Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 6
- Registration Number
- NCT05308901
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 725
- Registration Number
- NCT05301842
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05303090
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Elizabeth K. Lee MD
- Target Recruit Count
- 31
- Registration Number
- NCT05296512
- Locations
- 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, United States
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-03-22
- Target Recruit Count
- 20
- Registration Number
- NCT05291052
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT05290220
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT05273554
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 4
- Registration Number
- NCT05263492
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
- Conditions
- Interventions
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Juntendo University
- Target Recruit Count
- 30
- Registration Number
- NCT05258279
- Locations
- 🇯🇵
Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
🇯🇵Saitama Cancer Center, Ina, Saitama, Japan
🇯🇵Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka, Japan
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
- Conditions
- Interventions
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2023-10-13
- Target Recruit Count
- 90
- Registration Number
- NCT05250843
- Locations
- 🇨🇳
Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.